Cytokinetics (CYTK) Tops Q2 EPS by 13c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $68.78 -1.63%
Revenue Growth %: +1,966.3%
Financial Fact:
General and administrative: 7.22M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +1,966.3%
Financial Fact:
General and administrative: 7.22M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.50), $0.13 better than the analyst estimate of ($1.63). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $17.09 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Axion Minerals plans flow-through private placement of up to $440K
- SmartKem (SMTK) files for 15.13M share offering by selling stockholders
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
